1. Academic Validation
  2. NADPH oxidase-induced oxidative stress in the eyes of hypertensive rats

NADPH oxidase-induced oxidative stress in the eyes of hypertensive rats

  • Mol Vis. 2021 Apr 2;27:161-178.
Álvaro Santana-Garrido 1 2 Claudia Reyes-Goya 1 Carmen Fernández-Bobadilla 1 Antonio J Blanca 1 Helder André 3 Alfonso Mate 1 2 Carmen M Vázquez 1 2
Affiliations

Affiliations

  • 1 Departamento de Fisiología, Facultad de Farmacia, Universidad de Sevilla. CL Profesor García González, Sevilla, Spain.
  • 2 Epidemiología Clínica y Riesgo Cardiovascular, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío - Consejo Superior de Investigaciones Científicas - Universidad de Sevilla. Avda. Manuel Siurot s/n, Sevilla, Spain.
  • 3 Department of Clinical Neuroscience, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden.
PMID: 33907371
Abstract

Purpose: Increased Reactive Oxygen Species (ROS) released by NADPH Oxidase and inflammation are associated with arterial hypertension and eye diseases associated with high blood pressure, including glaucoma, retinopathies (e.g., age-related macular degeneration), and choroidopathies affecting ocular function; however, the mechanisms underlying these adverse outcomes remain undefined. The present study was designed to highlight the importance of oxidative stress in severe hypertension-related eye damage.

Methods: Male Wistar rats (n = 7, unless otherwise specified for specific experiments) were administered an oral dose of 30 mg of Nω-nitro-L-arginine methyl ester (L-NAME) per kilogram of bodyweight and day for 3 weeks; chronic administration with L-NAME is a validated experimental approach resulting in severe hypertension secondary to nitric oxide (NO) depletion and subsequent vasoconstriction in the systemic circulation. Upon treatment completion, histomorphometric studies, NADPH Oxidase activity, and ROS production were measured in eyecup homogenates and paraffin-embedded sections from control and L-NAME-treated Animals. In addition, immunohistofluorescence, western blotting, and Real-Time PCR (RT-qPCR) analyses were performed in the eye and the retina to evaluate the expression of i) NADPH Oxidase main isoforms (NOX1, NOX2, and NOX4) and subunits (p22phox and p47phox); ii) glial fibrillary acidic protein (GFAP), as a marker of microglial activation in the retina; iii) antioxidant enzymes; and iv) endothelial constitutive (eNOS) and inflammation inducible (iNOS) nitric oxide synthase isoforms, and nitrotyrosine as a versatile biomarker of oxidative stress.

Results: Increased activity of NADPH Oxidase and superoxide anion production, accompanied by transcriptional upregulation of this Enzyme isoforms, was found in the retina and choroid of the hypertensive rats in comparison with the untreated controls. Histomorphometric analyses revealed a significant reduction in the thickness of the ganglion cell layer and the outer retinal layers in the hypertensive Animals, which also showed a positive strong signal of GFAP in the retinal outer segment and plexiform layers. In addition, L-NAME-treated Animals presented with upregulation of nitric oxide synthase (including inducible and endothelial isoforms) and abnormally elevated nitrotyrosine levels. Experiments on protein and mRNA expression of antioxidant enzymes revealed depletion of superoxide dismutase and Glutathione Peroxidase in the eyes of the hypertensive animals; however, glutathione reductase was significantly higher than in the normotensive controls.

Conclusions: The present study demonstrated structural changes in the retinas of the L-NAME-treated hypertensive Animals and strengthens the importance of NADPH Oxidase as a major ROS-generating Enzyme system in the oxidative and inflammatory processes surrounding hypertensive eye diseases. These observations might contribute to unveiling pathogenic mechanisms responsible for developing ocular disturbances in the context of severe hypertension.

Figures
Products